The ability to specifically target a cell-type is important for the development of vectors for in vivo gene therapy. In order to produce retrovirus vectors targeting ovarian cancer cells, which specifically overexpress ␣ folate receptor (␣FR), a single chain antibody was fused as an N-terminal extension of the ecotropic and amphotropic murine leukemia virus (MLV) envelope glycoproteins. Vector particles bearing the modified glycoproteins were produced and analysed. Although conventional FACS studies indicated that viral particles bearing the modified Env could bind to ovarian cancer cells, targeted infection was not achieved. The initial step of viruscell interaction was further studied using an immunofluorescence technique, which allows visualisation of single retrovirus particles. Vectors bearing chimeric or wild-type
Introduction
The possibility of producing targeted vectors has been extensively explored by redirecting retrovirus tropism (reviewed in Ref. 1) . In order to generate vectors targeted to specific human cell types (eg cancer cells), viruses originally not infectious for human cells, such as Moloney MLV (MoMLV), were first engineered. 2 Ligands, such as single chain fragments of antibody variable regions (scFv) and cytokines, have been inserted into the MoMLV envelope glycoprotein as an addition or a replacement of the original receptor binding domain. [2] [3] [4] [5] [6] [7] [8] The various chimeric envelope glycoproteins that have been described could correctly fold and were efficiently incorporated into viral particles, while the inserted ligands were shown to maintain their original binding ability. Virus-cell interactions have been primarily studied using FACS analyses of virus-cell complexes labelled with anti-SU (surface glycoprotein subunit of Env) antibodies. The results indicated that virus particles pseudotyped with chimeric ecotropic Env could specifically bind to human cells expressing the targeted cell-surface molecule. How-glycoproteins bound equally well to cells with or without the targeted receptor, although soluble chimeric glycoproteins bound specifically to FBP. Our results indicate that the incorporation of specific ligands to the virus envelope does not necessarily result in significant enhancement of vector particle binding. A similar interaction was also observed using Env-defective virus particles, suggesting that cellular factors incorporated into the lipid envelope play a dominant role in promoting initial adsorption of virus particles to cells. Significant implications arise from these observations on the interpretation of previous reports on 'targeted' vectors, and for the development of vectors for in vivo gene therapy protocols. Gene Therapy (2001) 8, 1088-1096.
ever, the modified vectors were only minimally or not at all infectious for the targeted cells, implying that such a specific binding does not result in infectivity. 2, [7] [8] [9] [10] [11] [12] It is plausible that, in contrast to the wild-type envelope glycoprotein, the chimeric envelope glycoprotein lacks the ability to trigger the appropriate post-binding conformational changes leading to the fusion between the virus and the cell membranes. 13 As it became clear that the interaction between the original virus receptor and the envelope glycoprotein was required to achieve efficient virus-cell fusion and cannot be substituted by the interaction of a nonviral ligand-receptor, a virus naturally infectious for human cells was engineered in order to enhance its binding to a specific human cell type. Ligands were therefore inserted into the envelope glycoprotein of amphotropic MLV, whose receptor Pit-2 is expressed by a wide range of mammalian cells, including those of human origin. Once again, binding studies performed by FACS indicated that virus particles bearing the modified amphotropic Env glycoproteins preferentially bound to cells expressing the targeted antigen. However, depending on the cell surface molecule targeted by the chimeric glycoprotein, virus infectivity was impaired. While preferential infection was obtained with virions targeting the high molecular weight melanoma associated antigen (HMWMAA), 10 impairment of virus transduction was observed with virions targeting the EGF (epidermal growth factor) and the IGF (insulin growth factor) receptors. ␣FR is a 38 kDa GPI-linked high-affinity folate binding protein and is over-expressed in 90% of non-mucinous ovarian carcinomas. As ␣FR is not expressed in most normal tissues, it represents a highly selective tumour marker [15] [16] [17] and an attractive target to selectively direct cytotoxic agents to ovarian cancer cells. Both folic acid and monoclonal antibodies against ␣FR have been used in order to deliver toxins, chemotherapy and radiotherapy agents to ovarian cancer cells. 18 Adenovirus vector infection was also redirected to ␣FR positive cells, using a molecular bridge formed by an antifiber antibody conjugated with folic acid. 19 A highly specific monoclonal antibody, MOv18, has been extensively used to study ␣FR and to direct CTLs to the site of the malignancy. 20 In order to target gene delivery to ovarian cancer cells, we have generated retrovirus vectors incorporating a scFv derived from MOv18. Here we describe the binding and infectivity properties of such virus particles.
Results
Construction and expression of the glycoproteins incorporating MOv18 scFv Copy DNAs derived from the MOv18 (monoclonal antibody-expressing C43-8) hybridoma cell line, 15, 17 were used to prepare light and heavy chain complementarity determining regions (CDRs) of MOv18 MAb with optimal affinity for ␣FR. These CDRs were then inserted into the pT7blue vector to create and express a scFv (scMOv18) which was shown to maintain the binding specificity of the full size antibody (M Fling, unpublished data). The scMOv18 is a 266 aa polypeptide composed of the variable regions of the antibody heavy and light chains connected with a (Gly 4 Ser) 5 linker. ScMOv18 was inserted into the amphotropic and ecotropic envelope glycoproteins in position +1 (Figure 1 ). The amphotropic and ecotropic MLV envelope glycoproteins were expressed in FBASALF and FBMOSALF plasmids respectively. 7, 21 The expression of modified envelope glycoproteins and their incorporation into viral particles were then investigated. TELCeB6 packaging cells, 21 were transfected with AmphoMOv and EcoMOv. Stable transfectants were selected after treatment with phleomycin. Twenty-five clonal populations each from EcoMOv and AmphoMOv transfectants were isolated and screened. The clones producing the highest viral titre on NIH 3T3 cells were used for further investigations. Env expression and incorporation into viral particles were analysed by Western blot assay. Cell-free viral pellets obtained by ultracentrifugation of culture supernatants were analysed. Simultaneous detection of SU envelope protein and P30 capsid proteins was performed using polyclonal antibodies against RLV SU and RLV P30 and an HRP conjugated secondary antibody. Chemiluminescence (Figure 2 ) revealed 70 kDa and 98 kDa bands in samples derived from wild-type and chimeric Env transfectants, respectively, consistent with the insertion of the 266aa scFv. These results indicate that the chimeric envelope glycoproteins are correctly processed and incorporated into viral particles.
The intensity of the 30 kDa bands representing the capsid protein P30 suggested that all samples analysed were similar for virus core content. However, weaker bands were detected for chimeric SU. Assuming that the polyclonal antibody used to detect SU can recognise wildtype proteins as efficiently as chimeric proteins, this observation would indicate either that a smaller amount of AmphoMOv and EcoMOv glycoproteins are incorporated into viral particles compared with wild-type Env proteins, or that fewer virions were pseudotyped by chimeric Env than wild-type Env proteins. To explore these two possibilities, direct visualisation of envelope glycoproteins on viral particles was performed using immunofluorescence staining. Viral supernatants were visualised on microscope slides. SU was detected in most virus particles derived from samples pseudotyped with chimeric, as well as wild-type Env, indicating that the large majority of the viral particles incorporate Env molecules ( Figure 3 ). As negative control, virus particles produced by Env-less TELCeB6 cells stained only for capsid. These results demonstrate that the chimeric amphotropic and ecotropic SU are correctly processed and incorporated into the majority of the viral particles, but possibly at a lower stoichiometry relative to capsid proteins. Chimeric envelope glycoproteins bind to ␣FR Before investigating the binding properties of the chimeric envelope glycoprotein, ␣FR expression was monitored on several ovarian cancer cells by indirect immunofluorescence staining followed by FACS analyses. Cells were stained using the mouse monoclonal antibody MOv18. The Igrov-1 cell line was selected among a panel which included seven ovarian cancer cell lines (CH1, A2780, 41M, Skov-3, HX62, PXN94 and Igrov-1) based on the highest level of ␣FR surface expression ( Figure 4 , data shown only for Igrov-1). ␣FR expression was similarly analysed on human epidermoid A431 and murine NIH 3T3 cells expressing ␣FR upon transfection with the relevant cDNA (A431-␣FR and NIH 3T3-␣FR respectively). 22 Results obtained ( Figure 4) show that the original MOv18 antibody possesses high reactivity for all three cell lines expressing ␣FR. These cells were therefore considered appropriate to investigate the binding and the infectivity properties of the chimeric viruses incorporating scMOv18.
We have previously shown that the use of anti-SU antibodies in conventional FACS analysis of cells exposed to MLV-A and MoMLV supernatants allows detection of soluble SU interacting with its specific receptor, rather
Figure 4 Surface expression of ␣FR in ovarian cancer cells and stable transfectants. Ovarian cancer cells Igrov1, epidermoid A431 cells, murine 3T3 cells and stable ␣FR transfectants (A431-␣FR and 3T3-␣FR) were stained using mouse MOv18 antibody (clear histograms) or irrelevant mouse immunoglobulins (grey histograms) and analysed by FACS.
than virus particles bound to cells. 23 FACS can therefore be used to investigate either the expression level of a specific viral receptor on the cell surface or the binding properties of the viral glycoprotein to a cellular receptor whether it is a component of a virus particle or not.
␣FR-negative (A431) and ␣FR-positive (A431-␣FR and Igrov-1) cells were incubated with viral supernatants, stained using anti-SU antibody followed by FITC-conjugated secondary antibody, and analysed by FACS. The fluorescence produced using different viral pseudotypes was compared with the background fluorescence produced using Env-defective viral supernatant (TELCeB6). Shifts, representing SU binding on the cell surface, were only observed when FBP-positive cells were incubated with AmphoMOv and EcoMOv supernatants ( Figure 5 ). Conversely, no binding was detected using wild-type supernatants on FBP-positive or -negative cells, or when FBP-negative cells were exposed to chimeric viral supernatants. Unexpectedly, amphotropic Env did not show significant binding to A431 and Igrov-1 cells, which are Gene Therapy permissive to MLV-A infection. Moreover, using the same amphotropic viral supernatant, binding was observed on other human cells (TE671, data not shown), probably indicating that the level of the amphotropic receptor, Pit-2, in the A431 and Igrov-1 cells was too low to allow FACS detection of SU binding.
In order to demonstrate the specificity of the interaction between the chimeric glycoproteins and the cell surface, soluble MOv18 antibody was used to compete with the chimeric glycoproteins for the binding of ␣FR. Addition of 100 g/ml of MOv18 to viral supernatants abolished the binding of chimeric SU to FBP positive cells, proving that the chimeric glycoproteins bound to the cells through the specific interaction between MOv18 moiety and ␣FR on the cell surface ( Figure 5 ). In conclusion, in the context of the amphotropic and ecotropic envelope glycoproteins, the scFv preserves its original binding specificity and causes chimeric glycoproteins to interact with the nonviral receptor.
␣FR-scFvMOv18 interaction impairs viral infectivity
The infectivity of EcoMOv and AmphoMOv LacZ pseudotypes on FBP-positive and -negative cells was investigated. Subconfluent cultures of NIH 3T3, NIH 3T3-␣FR, A431, A431-␣FR and IGROV1 cells were infected with serial dilutions of viral supernatants harvested from confluent packaging cells. Viral titre was determined 2 days after infection after LacZ staining and was expressed as c.f.u./ml ( Figure 6 ). The infectivity of the chimeric viruses compared to that of wild type viruses on NIH 3T3 and A431 cells was 10-100 fold lower, suggesting that the insertion of the scFv partially compromised the function of the amphotropic and ecotropic envelope glycoproteins ( Figure 6 ) as found with other ligands. [24] [25] [26] [27] The ecotropic chimera, EcoMOv, was not infectious for any human cell line (data not shown), despite the expression of ␣FR, indicating that the interaction between chimeric Env and ␣FR, observed by FACS, failed to expand the ecotropic viral tropism, originally restricted to rodent cells. However, when EcoMOv was used to infect murine NIH 3T3 cells, its titre was 10-fold lower for cells expressing ␣FR than cells not expressing ␣FR, suggesting that the interaction of the chimeric virus with ␣FR caused a reduction of infectivity (Figure 6a ). Similarly, AmphoMOv produced a 10-fold lower titre in A431-␣FR than A431 (Figure 6b ). In contrast, viral titre of wild-type virions was similar in the presence or absence of ␣FR expression. In order to demonstrate that the decrease of infectivity of chimeric viruses on ␣FR-positive cells was caused by the specific interaction between ␣FR and the modified viral glycoproteins, 100 g/ml of soluble MOv18 antibody was added to the viral supernatants during infection. The infectivity of EcoMOv and AmphoMOv viruses on 3T3-␣FR and A431-␣FR cells was restored almost to the levels produced on FBP-negative cell lines. Similar results were produced using the ovarian cancer cell line Igrov-1. AmphoMOv virus infected Igrov-1 cells very poorly, but 10-fold higher infectivity was observed when soluble MOv18 was added to the viral supernatant (Figure 6c ).
Display of scFv is not sufficient to redirect viral binding As reported previously, 23 immunofluorescence staining of viral capsid followed by confocal microscopy analysis can be used to detect binding of viral particles to cells. Viral binding was similarly tested on A431 and A431-␣FR cell cultures. As shown in Figure 7 , a similar number of virions was detected in all cases, when ␣FR-positive or -negative cells were incubated with wild-type, chimeric or Env-defective viral particles. Similar binding of chimeric compared to wild-type or Env-defective particles was detected after shorter (5, 15, 30 min) or longer (2 h) exposure times (data not shown). These results indicate that the addition of scMOv18 to the N-terminus of the viral glycoprotein failed to redirect or enhance vector particle binding to cells expressing ␣FR. Moreover, the observation that a similar amount and rate of viral binding was detected when using Env-defective particles or any other pseudotype suggests that Env-independent interaction is the major mechanism mediating the initial adsorption of the viral particle to the cell, even when a scFv is displayed on the viral surface.
Using FACS analysis we have shown that addition of soluble MOv18 antibody specifically inhibits binding of chimeric Env to ␣FR-positive cells. In order to assess the role of the chimeric envelope glycoproteins on the initial binding of viral particles, soluble MOv18 was used to compete for ␣FR binding on the cell surface (Figure 7) . Virus particle binding to ␣FR-positive cells was not significantly affected by soluble antibody treatment, suggesting that the initial interaction of chimeric virions to ␣FR-positive cells does not involve binding to ␣FR. This result confirms that Env-independent mechanisms are the main determinants of initial virus adsorption.
Discussion
We have generated chimeric MLV vectors displaying a single chain antibody (scMOv18) directed against ␣FR, the ovarian tumour-associated antigen. ScMOv18 was incorporated into MLV envelope glycoproteins and assembled into virus particles. The ecotropic and the amphotropic chimeric SUs acquired the ability to bind ␣FR-positive cells. However, the interaction between chimeric envelope glycoproteins and the targeted receptor did not result in redirected or enhanced infectivity of the viral particles, reminiscent of previous attempts of retrovirus targeting. 2, [7] [8] [9] [10] [11] [12] We further demonstrated that the binding of vector particles to cells with or without target molecules was not affected by display of the scFv on the vector particle.
The development of an immunofluorescence technique for the visualisation of retroviral particles has provided a useful tool to investigate the binding of retroviral particles to the cell surface. 23 While FACS analyses suggested preferential binding of chimeric virus to ␣FR-positive cells, confocal microscopy revealed that a similar amount of virus can bind to both FBP-positive and -negative cells, regardless of the incorporation of ScMOv18. These results are consistent with our previous data, 23 where soluble SU molecules derived from MLV-A, rather than intact virus particles, are responsible for producing the fluorescent shift detected by FACS. It is therefore likely that, as in the case of amphotropic virus on human cells, FACS would detect soluble chimeric SU binding to ␣FR-positive cells, rather than binding of intact viral particles. In previous reports, the interpretation of binding data, obtained by FACS using anti-SU antibodies, led to the conclusion that retroviruses bearing chimeric Env could specifically interact with cells expressing a targeted surface molecule through the binding of a heterologous ligand. [8] [9] [10] [11] [12] 24, 26, 28 In the light of the results described here, it is probable that the specific detected binding was due to soluble SU, rather than virus particles. A cautious reinterpretation of previous studies may therefore be required.
Microscopy observations revealed that viral particles bearing either chimeric, wild-type or no Env, bind to cells with and without ␣FR at a similar rate. These results indicate that the presence of the scFv on the surface of the viral particle may not be sufficient to significantly enhance particle binding on cells expressing ␣FR. As no Figure. No difference between binding of the different pseudotypes or Env-defective particles was observed, Envindependent binding seems to have a 'dominant' effect in promoting virus adsorption to cells, regardless of the presence of the exogenous ligand on the virus particle surface. It has often been assumed that retroviral particles bind to the cell surface through the interaction of SU with its specific receptor and, consequently, that no significant viral binding occurs in the absence of Env or its specific receptor. Our results raise the possibility that MLV relies on Env-independent mechanisms to bind to the cell surface before interacting with its specific receptor. MLV binds to and infects lymphoid cells very poorly, although the specific virus receptor is expressed by these cells at high levels, 23 indicating that Env-receptor interaction was not sufficient to provide an efficient adsorption mechanism. Env-independent binding may have a functional importance by providing efficient adsorption and favouring the subsequent interaction with the specific viral receptors required for particle internalisation.
Figure 7 Virus binding to ␣FR-negative and -positive A431 cells. A431 and A431-␣FR cells, grown on coverslips, were incubated with viral supernatants at 37°C for 1 h, fixed, permeabilised and processed for immunostaining of capsid. The viral supernatant tested is marked on the
The nature of such Env-independent binding is unclear. Receptor sites for Env-independent adsorption could be more accessible than receptors for Env-dependent binding. For example, Env-independent binding could involve components of the extracellular matrix, such as glycosaminoglycans or proteoglycans. In this case Env-independent binding would provide a capture mechanism more efficient than Env-mediated mechanisms. The envelope binding site on receptor for ecotropic MoMLV (Rec-1) is situated very close to the membrane 29 and therefore it is likely to provide a poorly exposed docking site for the virus. Similarly, the amphoGene Therapy tropic receptor and other surface molecules, including ␣FR, may represent docking sites only poorly accessible for the viral particle. In collaboration with SJ Walker and S Devereux (Department of Haematological Medicine, Kings College Hospital, London, UK), we have recently shown that a glycosaminoglycan, heparin, binds to MLV particles with or without Env and inhibits both Env-independent binding and transduction at a similar concentration range. These results may support the idea that glycosaminoglycans or proteoglycans on cell surface play a role as virus docking sites. However, no evidence for an interaction between the virus and cell surface proteoglycans was found as the Env-independent attachment of MLV to proteoglycan-deficient mutant Chinese hamster ovary (CHO) cells and to wild-type CHO cells was the same. 30 Interaction between ScMOV18 chimeric Env on virion surface and cell surface ␣FR should occur as the step after initial virus adsorption. However this interaction did not result in preferential infection by the chimeric vectors of ␣FR-positive cells compared to ␣FR negative cells. The ecotropic envelope chimera could not infect human ovarian cancer cells. This indicates that the interaction between the modified envelope glycoprotein and ␣FR does not catalyse fusion between the virus and the cell membranes and therefore cannot substitute for the interaction between the original Env and its receptor. The infectivity of the amphotropic chimeric virus for human cells expressing ␣FR and that of ecotropic chimeric viruses for murine cells expressing ␣FR was not enhanced, but rather partially impaired as a consequence of the interaction between the modified Env and the targeted receptor. These results are reminiscent of previous data describing retrovirus vectors targeting to the receptors for epidermal growth factor (EGF), where the interaction of the foreign ligand with the nonviral receptor may be responsible for driving the virus into degradative cell compartments, such as lysosomes. 7 However, this mechanism may not be applicable to ␣FR as only 10% of receptors in ovarian cancer cell lines are internalised. 31 Alternatively the interaction between ScMov18 moiety and ␣FR may interfere with binding of the original viral receptor to the viral SU domain or the post-binding events triggering fusion between the cell and the virus membrane. Overall, the results indicate that ␣FR belongs to a class of surface molecules that do not favour viral infection.
In conclusion, we have shown that the virus particles bind to the target cells in an Env-independent manner and that the modification of the binding property of the envelope glycoprotein would not necessarily change the property of the virus particle in the initial cell attachment. Virions with broad adhesion properties cannot be used to specifically target a subset of cells at the adsorption stage. Accordingly, the strategy to generate targeted MLV vectors characterised by specific cell binding seems not to be as straightforward as initially thought and such attempts have been unsuccessful in most cases. 2, [6] [7] [8] [9] [11] [12] [13] [14] Additionally, Env-independent binding of MLV could produce a default viral adsorption to a variety of cell types, which may result in wastage of gene therapy vectors in compartments not relevant for in vivo applications. Production of targeted vectors may require the development of virions lacking nonspecific adhesion properties. Further investigation of the nature of the Env-independent binding, as well as a search for cells which do not express the adhesive factor(s) may be useful for this goal. However, unless alternative mechanisms are used to mimic rapid adsorption of virions to the specific cell membrane, such vehicles may suffer from a considerably lower infectivity.
Materials and methods

Plasmid engineering
Messenger RNA was isolated from the C43-8 hybridoma cell line, converted to cDNA and cloned into expression vectors. Six heavy chain and three light chain variants were screened by sandwich ELISA for binding to ␣FR. The light and heavy chain variants that gave optimal binding were combined into a scFv expression vector (pT7blue, Novagen, Madison, WI, USA). Binding was also confirmed by expression and purification of the scFv from COS-7 cells followed by sandwich ELISA (data not shown). The construction of chimeric envelope glycoproteins was carried out following standard molecular biology techniques. 32 Site-directed mutagenesis and insertion of restriction sites were performed using the Quickchange site directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The ScMOv18 was cloned into pT7blue flanked by a SfiI site and a NotI site, respectively, at its 5′ and 3′ ends. A SfiI restriction site in the C57 Friend LTR of FBMOSALF 7 was deleted using the following oligonucleotides: 5′CGGCCCGGTCGGCGCCGGCCCGA GGC3′ and 5ЈGCCTGGGCCGGCGCCGACCGGGCCG3′. SfiI and NotI restriction sites were inserted into the ecotropic env by site-directed mutagenesis. SfiI and NotI restriction sites were sequentially inserted in position +1 using the following oligonucleotdes. For insertion of SfiI: 5′CAGAGGGGTCAGTACTGCGGCCCAGCCGGCC GCTTCGCCCGGCTCCAG3′ and 5′CTGGAGCCGGGCG AAGCGGCCGGCTGGGCCGCAGTACTGACCCCTCTG3′. For insertion of NotI: 5′GCGGCCCAGCCGGCCGCGG CCGCTTCGCCCGGCTCCAG3′ and 5′CTGGAGCCGG CGAAGCGGCCGGGGCCGGCTGGGCCGC3′. The modified amphotropic env construct already containing SfiI and NotI restriction sites in position +1 was kindly provided by S Russell (Mayo Clinic, MN, USA).
7 ScFv MOv18 was directly cloned into the modified FBMOS-ALF and FBASALF plasmids and chimeric Envs (EcoMOv and AmphoMOv, respectively) were established. The correct mutagenesis and cloning were confirmed by DNA sequencing.
Cells and viruses
Murine NIH 3T3 cells, human epidermoid vulval carcinoma A431 cells, their derivatives stably expressing ␣FR, NIH 3T3-␣FR 33 and A431-␣FR, 22 human ovarian carcinoma Igrov1 cells (kindly provided by Dr J Benard, Institute G Roussy, Villejuif, France) and all producer cell lines were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco BRL, Paisley, UK) supplemented with 10% (v/v) heat inactivated fetal calf serum (FCS), penicillin G (100 U/ml) and streptomycin (100 mg/ml) and cell cultures were maintained at 37°C in 5% CO 2 . Packaging cell lines were grown in the presence of 50 g/ml phleomycin (CAYLA, Montaudran, France) and 6 g/ml blasticidin-S (ICN, Basingstoke, UK). TELCeB6, TELCeB6/ AF-7 and TELCeB6/MOF are helper free packaging cells producing MLV-based retrovirus vector particles which encode the MFGnlslacZ genome and bear no envelope, 4070A amphotropic MLV envelope and ecotropic Moloney MLV envelope glycoproteins, respectively.
10,21
Transfection, virus production and infection Plasmid expressing envelope constructs were introduced into TELCeB6 cells by Lipofectamine reagent (Gibco BRL) following the manufacturer's guidelines. After 48 h, cells were cultured in medium containing 50 g/ml phleomycin. The selection medium was replaced every 3 days and after 2-3 weeks single resistant colonies were isolated and screened for virus production.
The virus used for transduction and binding studies was harvested from growth medium of confluent cultures after overnight incubation. Supernatants were filtered through 0.45 m filters (Sartorius, Goettingen, Germany) before use. For virus transduction studies, target cells were seeded the day before infection at a concentration of 5 × 10 4 cells in 0.5 ml in a well of a 24 well tissue culture plate. Cells were incubated with 0.5 ml dilutions of virus supernatants for 4 h at 37°C in the presence or absence of purified MOv18 antibody. Virus inoculum was then replaced with fresh medium. After 48 h, cells were stained using X-gal (5-bromo-4-chloro-3-indolyl-␤-galactopyranoside) as previously described. 34 Clusters of stained cells were attributed to a single infection event and titre was expressed as LacZ colony-forming units (c.f.u.) per ml of virus supernatant.
Antibodies
Goat polyclonal antibodies (Quality Biotech Inc., Camden, NJ, USA) were used to detect MLV capsid pro-teins (anti-RLV p30) and MLV surface envelope proteins (SU) (anti-RLV gp69/71). 83A25 rat monoclonal IgG which recognises MLV SU, was kindly provided by LH Evans. 35 Fluorescein isothiocyanate (FITC)-and Texas red-conjugated donkey IgG against goat IgG (Jackson, West Grove, PA, USA), FITC-conjugated donkey IgG against rat IgG (Jackson) were used as secondary antibodies in immunofluorescence experiments. Mouse IgG (Sigma, Poole, UK) were used as irrelevant antibody in FACS experiments. HRP-labelled anti-goat antibody (Sigma) was used as secondary antibody in Western blot assay. For competition studies, purified mouse monoclonal MOv18 antibody (Centocor, The Netherlands) was used at the indicated concentration.
Western blot Six ml of virus supernatant was harvested from a confluent culture of producer cells in DMEM supplemented with 2% FCS. Supernatant was filtered through a 0.45 m filter and pelleted by centrifugation at 100 000 g in a SW40 rotor (Beckman, High Wycombe, UK) for 1 h at 4°C. The virus pellet was resuspended in 100 l of PBS and stored at −80°C. 15 l of each sample to be loaded on gel were mixed 1:1 with gel loading buffer (100 mm Tris pH 6.8, 4% SDS, 20% glycerol, 5% 2-␤-mercaptoethanol, 0.02% bromophenol blue), boiled for 3 min and run on 12% polyacrylamide gels. Proteins were transferred on to nitrocellulose membrane (Amersham, Amersham, UK). The blots were washed in Tris-buffered saline (TBS; 25 mm Tris-base pH 7.4, 140 mm NaCl, 5 mm KCl), 0.1% Tween 20 (TBS-Tween) for 10 min and blocked in TBS-Tween containing 5% non-fat milk powder (TTM) for 1 h at room temperature. Membranes were incubated with 1:1000 goat anti-RLV SU and 1:10 000 goat anti-RLV P30 in TTM for 1 h at room temperature, washed three times in TBS-Tween and incubated with 1:5000 HRPlabelled anti-goat antibody in TTM for 1 h at room temperature. After the membrane were washed three times with TBS-Tween and once with TBS, protein detection was performed using the enhanced chemiluminescence system (ECL, Amersham) according to the manufacturer's instructions and using Kodak Biomax MR film (Hertfordshire, UK).
Immunofluorescence staining
To observe virus particles adsorbed to glass slides (Sigma), 50 l of viral supernatants were incubated on the slide surface for 1 h at 37°C in the presence of 8 g/ml of polybrene (Sigma). Slides were washed once with PBS, fixed with 4% paraformaldehyde for 15 min at room temperature and permeabilised with 0.2% Triton X-100 for 15 min at room temperature. These samples were processed for simultaneous staining of capsid and envelope glycoprotein using polyclonal goat anti-RLV P30 antibody and monoclonal rat anti-MLV-SU antibody, 83A25, followed by Texas red and FITC-conjugated secondary antibodies, respectively. To visualise virus particles bound to cells, cells were seeded on to 5-cm plastic tissue culture dishes at a concentration of 1 × 10 6 cells/dish. After overnight incubation, samples were incubated with 2 ml of neat viral suspensions for 1 h at 37°C in the absence or presence of 100 g/ml of purified MOv18 antibody. Cells were then washed five times with PBS, fixed with 4% paraformaldehyde for 15 min at room temperature and permeabilised with 0.2% Triton X-100
Gene Therapy for 15 min at room temperature. These samples were processed for staining of capsid using polyclonal goat anti-RLV P30 antibody and FITC-conjugated secondary antibody.
After fixation and permeabilisation, samples were washed with PBS and incubated with anti RLV P30 antibody diluted 1/3000 or with neat 83A25 hybridoma supernatant for 45 min at room temperature. Samples were washed three times with PBS, incubated with 1/200 dilution of secondary antibodies for 45 min at room temperature. After extensive washing with PBS and a final wash with distilled water, samples were mounted with immunofluorescence mounting medium (Dako, Ely, UK) and analysed by confocal microscopy using an MRC 1024 BioRad microscope equipped with a krypton-argon laser and Lasersharp software (BioRad, Hemel Hempsted, UK) with Kalman filtration.
FACS analysis
Cells were washed in PBS and detached with 10 mm EDTA in PBS. For Env binding assays, 10
6 cells were incubated with 1 ml of virus suspensions for 1 h at 37°C before antibody staining. Samples were subsequently washed three times with ice cold PBS containing 1% bovine serum albumin and 0.1% sodium azide (PBA). Cells were incubated with primary antibody, washed three times with PBA and incubated with the secondary antibody for 45 min at room temperature. After a final wash, samples were analyzed by FACScan (Becton Dickinson, Oxford, UK). Where indicated, for competition studies, soluble MOv18 antibody was added to viral supernatants at a final concentration of 100 g/ml.
